Understanding Lyophilised Peptides
How lyophilisation preserves peptide integrity, what to expect when you receive a lyophilised vial, and best practices for handling before reconstitution.
Scientific background / literature overview only. Discussion of published research does not describe the intended use of Novex Peptide products.
Introduction
Lyophilisation — freeze-drying — is the standard method for preserving research peptides during storage and shipping. The process removes water by sublimation under vacuum, leaving a stable dry powder that can be stored for extended periods at low temperatures.
The Lyophilisation Process
Freezing
The peptide solution is frozen rapidly, typically at -40°C to -80°C. Rapid freezing produces small ice crystals, which minimise damage to the peptide structure.
Primary Drying
The chamber pressure is reduced below the triple point of water, and temperature is gradually raised. Ice sublimes directly from solid to vapour without passing through a liquid phase.
Secondary Drying
Residual bound moisture is removed by raising the temperature further under continued vacuum. Final residual moisture content is typically below 1-3%.
Appearance of Lyophilised Peptides
Lyophilised peptides may appear as a fluffy white powder, a compact cake, or small granules. The appearance varies with the peptide, buffer composition, and lyophilisation parameters. A vial that appears empty or only partially filled is normal — the peptide may be spread thinly across the inner surface.
Pre-Reconstitution Handling
Stability Considerations
Lyophilised peptides are generally stable for 1-2 years when stored at -20°C. Peptides containing methionine, cysteine, or tryptophan residues are more susceptible to oxidation and may require storage at -80°C under inert gas.
Research Limitations
All handling guidance applies to laboratory research use only. Lyophilised peptides supplied by Novex Peptide are not intended for human use or clinical applications.
References
- 1.Bauer JF. Lyophilization: An Overview. In: Encyclopedia of Pharmaceutical Technology. 2002.
- 2.Carpenter JF, et al. Rational Design of Stable Lyophilized Protein Formulations. Biochemistry. 2002;41(15):4613-4620.
- 3.Tang X, Pikal MJ. Design of Freeze-Drying Processes for Pharmaceuticals. Pharm Res. 2004;21(2):191-200.
Research use only. This article is for educational purposes only and does not constitute advice for any application involving human use. No medical claims are made.
